A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation
Daping Xie,Congwei Han,Chonghao Chen,Zhencheng Liao,Senio Campos de Souza,Yiming Niu,João F. Mano,Lei Dong,Chunming Wang
DOI: https://doi.org/10.1016/j.bioactmat.2024.03.035
IF: 18.9
2024-04-24
Bioactive Materials
Abstract:Highlights • Intracellular ROS kinetics dictates antigen-presenting mode. • Sustained TLR2 activation triggers intracellular ROS kinetics required for cross-presentation. • A scaffold vaccine enabling "retention-and-release" for sustained TLR2 activation in DCs promotes cross-presentation. • The scaffold vaccine induces robust, CD8 + T cells-mediated anti-tumor immune responses in Apc min/+ transgenic mice. Cancer vaccination holds great promise for cancer treatment, but its effectiveness is hindered by suboptimal activation of CD8 + cytotoxic T lymphocytes, which are potent effectors to mediate anti-tumor immune responses. A possible solution is to switch antigen-presenting cells to present tumor antigens via the major histocompatibility complex class I (MHC-I) to CD8 + T cells – a process known as cross-presentation. To achieve this goal, we develop a three-dimensional (3D) scaffold vaccine to promote antigen cross-presentation by persisted toll-like receptor-2 (TLR2) activation after one injection. This vaccine comprises polysaccharide frameworks that "hook" TLR2 agonist (acGM) via tunable hydrophobic interactions and forms a 3D macroporous scaffold via click chemistry upon subcutaneous injection. Its retention-and-release of acGM enables sustained TLR2 activation in abundantly recruited dendritic cells in situ , inducing intracellular production of reactive oxygen species (ROS) in optimal kinetics that crucially promotes efficient antigen cross-presentation. The scaffold loaded with model antigen ovalbumin (OVA) or tumor specific antigen can generate potent immune responses against lung metastasis in B16-OVA-innoculated wild-type mice or spontaneous colorectal cancer in transgenic Apc Min/+ mice, respectively. Notably, it requires neither additional adjuvants nor external stimulation to function and can be adjusted to accommodate different antigens. The developed scaffold vaccine may represent a new, competent tool for next-generation personalized cancer vaccination. Graphical abstract A scaffold vaccine that promotes antigen cross-presentation to trigger CD8 + T cell-mediated anti-tumor immune responses . In this study, we discover that the kinetics of intracellular ROS, unexpectedly, dictates the mode of antigen presentation. Persistent production in moderate dose promotes antigen cross-presentation. To create optimal intracellular ROS kinetics for lysosomal disruption and antigen escape, we design a 3D injectable scaffold for the "retention-and-release" of a TLR2 agonist glycan upon subcutaneous implantation. Installation of tunable hydrophobic interactions between the scaffold and the "hooked" agonist enables sustained TLR activation in the abundantly recruited DCs in situ , which triggers consequently efficient cross-presentation of tumor antigens. The efficacy of this novel scaffold vaccine is subsequently undergoing comprehensive evaluations in both wild-type and transgenic mice against localized, metastatic, and spontaneous tumors. Download : Download high-res image (369KB) Download : Download full-size image
engineering, biomedical,materials science, biomaterials